FontsA A
ContrastA A
Newsletter sign-up
I agree with the regular receipt of the newsletter of BBMRI-ERIC. The subscription to the newsletter can be canceled at any time (see privacy notice) )

Completed Projects



Building data bridges and services between biological and medical infrastructures in Europe

Topic: FP7 INFRA-2011-2.3.2

Type of Action: CP-CSA Infra

Duration: 36 months

Start Date: 1 January 2012

BBMRI-ERIC full partner: as of 1 October 2014

Grant Agreement Nr: 284209


Coordinator: Janet Thornton

Total requested Grant by Consortium: € 10,494,998.69

Total requested Grant by BBMRI-ERIC: € 8,400.00

Linked Third Parties/BBMRI-ERIC Framework Agreement: none

Benefit/tasks for BBMRI-ERIC: Connecting BMS RIs


Lead by European Molecular Biology Laboratory: BioMedBridges (Building data bridges and services between biological and medical infrastructures in Europe) will form a cluster of the emerging biomedical sciences research infrastructures (BMS RIs) and construct the data and service bridges needed to connect them.

The BMS RIs are on the ESFRI (European Strategy Forum on Research Infrastructure) roadmap. The missions of the BMS RIs stretch from structural biology of specific biomolecules to clinical trials involving thousands of human patients. Most serve a specific part of the vast biological and medical research community, estimated to be at least two million scientists in Europe across more than 1,000 institutions from more than 36 ESFRI Member States and Associated Countries. Each of them brings together its own large community of users to build a coordinated infrastructure.

This process has already had a major impact on coordination of national infrastructures within each member state. Essentially all BMS RIs are distributed infrastructures, with nodes in many European member states.

List of Participants

European Molecular Biology Laboratory/ELIXIR, University of Oxford, Karolinska Institutet, Science and Technology Facilites Council, Heinrich Heine Universität Düsseldorf, Leibnitz-Institut für Molekulare Pharmakologie, Technische Universität München, Stazione Zoologica Anton Dohm, Erasmus University Medical Center Rotterdam, Technologie- und Methodenplattform für die vernetzte medizinische Forschung e.V, Helmholtz Zentrum München, Medizinische Universität Graz, Stichting VU-VUmc, Institut national de la santé et de la recherche médicale, University of Copenhagen, University of Helsinki/Institute for Molecular Medicine Finland, European Grid Infrastructure, CSC-IT Center for Science Ltd., University Medical Center Groningen, Consorzio Interuniversitario di Risonanze Magnetiche di Metalloproteine, Delivery of Advanced Network Technology to Europe


Completed Projects



European Medicines Research
TRAIning Network

Topic: FP7/2007-2013

Type of Action: IMI

Duration: 84 months

Start Date: 1 October 2009

BBMRI-ERIC full partner: as of 1 October 2015

Grant Agreement Nr: 115015


Coordinator: Mike Hardman

Total requested Grant by Consortium: €4,000,000.00

Total requested Grant by BBMRI-ERIC: €9,754.45

Linked Third Parties/BBMRI-ERIC Framework Agreement: none

Benefit/tasks for BBMRI-ERIC: Education & training platform, IMI (Innovative Medicines Initiative)


Lead by Astra Zeneca

EMTRAIN will establish a pan-European platform for education and training covering the whole lifecycle of medicines from basic research through clinical development to pharmaco-vigilance. The public consortium consists of the six pan-European biomedical research infrastructures from the ESFRI roadmap, that cover a broad spectrum of competencies from molecules to humans, with a pan-European dimension. The EFPIA consortium has considerable experience in training and education, management, pan-European geographical outreach, and an extensive external network of contacts. The participants, together with the coordinators of IMI&T topics will participate in the Strategic Co-ordination Board to ensure coordination between the IMI&T topics whereas the Steering Committee will supervise the management of the project. E&T (Education and Training) topics representatives will be invited to participate in work packages activities. Based on extensive mapping of existing resources and on a gap and overlap analysis (Work Package 3) the consortium will develop and implement a strategy for harmonisation and accreditation (Work Package 4) of Master level Work Package 5) and PhD programmes (Work Package 6) as well as continuous education programmes (Work Package 7). It will develop innovative concepts and methods in conjunction with the other topics (Work Package 8) that will support the content for the IMI education programmes. National implementation will be facilitated through contacts with university authorities, ministries of higher education, and through national liaison offices. After implementation in a core group of institutions, extension is planned both within countries represented and in additional countries (Work Package 4), with the support of a dissemination and communication activity (Work Package 9) The harmonisation and the modular nature of these programmes will allow trans-disciplinary curricula as well as trans-border mobility, and PhD programmes will be designed to foster industry/academia mobility and collaboration.

List of Participants

AstraZeneca, Genzyme, Novartis, Bayer, Pfizer, Roche, GSK, UCB, Novo Nordisk, Sanofi, Boehringer Ingelheim, Janssen Pharmaceuticals, Orion, Almirall, Ludnbeck, Esteve, Medizinische Universität Wien (ECRINpartner), Karolinska Insititute (EATRIS partner), KUK (ECRIN partner), UniMan (BBMRI partner) ECRIN-ERIC, BBMRI-ERIC, EMBL-EBI (ELIXIR partner), HZI (EATRIS partner), GIE-CERBM (Infrafrontier partner), UOX (Instruct partner), MRC-HU (ECRIN partner) Institute of Human Virology, Nigeria


Completed Projects



Biobanking and the
Cyprus Human Genome Project

Topic: H2020-WIDESPREAD-2014-1

Type of Action: FPA-SGA

Duration: 12 months

Start Date: 1 September 2015

Grant Agreement Nr: 664561


Coordinator:  Constantinos Deltas

Total requested Grant by Consortium: €460,637.50

Total requested Grant by BBMRI-ERIC:  €64,475.00

Linked Third Parties/BBMRI-ERIC Framework Agreement:

Benefit/tasks for BBMRI-ERIC: Work Package 5: Standards, ELSI Compliance and Data Management; Task 5.1: Standards/Procedures Adoption & Quality Processes; Task 5.2: ELSI Compliance; Task 5.3: Data Management Plan (raw data availability and Gold access policy); Task 5.1/Deliverable 5.1, Task 5.2/Deliverable 5.2, Task 5.3/Deliverable 5.3


Lead by University of Cyprus: The upgrading of MMRC into a CoE and its close partnership with the named Advanced Partners is a safe and sound strategy that will assist Cyprus over the next decade to enter large European networks and participate at ongoing and future epidemiological studies with mutual benefit to the Cypriot and the European patients.

List of Participants: University of Cyprus, Medical University of Graz/, BBMRI-ERIC, RTD Talos Limited


Completed Projects


Biobanking and Biomolecular Resources Research Infrastructure – Large Prospective Cohorts

Topic: INFRA-2012-1.1.9

Type of Action: CP&CSA

Duration: 57 months

Start Date: 1 February 2013 – 31 October 2017

BBMRI-ERIC full partner: as of 1 April 2014


Coordinator: Markus Perola

Co-Coordinator: Gertjan van Ommen

Total requested Grant by Consortium: €8,000,000.00

Total requested Grant by BBMRI-ERIC: €14,552.00

Linked Third Parties/BBMRI-ERIC Framework Agreement: none

Benefit/tasks for BBMRI-ERIC: BBMRI-LPC Forum, BBMRI-ERIC



Lead by UH-FIMM.
BBMRI-LPC unites the large study sets of the European Biobanking and Biomolecular resources Research Infrastructure (BBMRI) and the International Agency for Research on Cancer (IARC), thus achieving a worldwide unique scale of integration.

Specifically, we aim to:
1.      Evaluate/improve the harmonisation of individual data on health, lifestyle and other exposures;

2.      Develop/implement harmonised definitions of diseases;

3.      Improve biobanking and research technologies and develop innovative solutions facilitating high-quality, fair transnational access to samples and data;

4.      Provide free transnational access by users, through study proposals selected by an open, pan-European call;

5.      In the framework of these studies, generate and provide access to whole genome sequences, transcriptome, proteome, metabolome and methylome data;

6.      Build new public-private partnerships involving large-scale prospective cohorts, and strengthening existing ones, allowing transparent industrial access to academic expertise;

7.      Build a network transferring the expertise of established European large-scale biobanks to new biobank initiatives under development in other countries (BBMRI-LPC Forum).


List of Participants:

Helsingin Yliopisto (UH-FIMM); Academisch Ziekenhuis Leiden Leid Universitair Medisch Centrum (LUMC); Centre International de Recherche Sur le Cancer (IARC-WHO); Imperial College of Science, Technology and Medicine (ICL); Medizinische Universitat Graz MEDUNI Graz (MUG); Karolinska Institutet(KI); Genome Research Limited (WTSI); Academisch Ziekenhuis Groningen (UMCG); Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit un Umwelt GmBh (HMGU); Norges Teknisk Naturvitenskapelige Universitet (NTNU); Tartu Ulikool (UTARTU); Uppsala Universitet (UU); Centre Nacional D’Anàlisi Genòmica Fundacio Centre de Regulacio Genomica (CNAG-CRG); Cambridge Protein Arrays LTD (CPA); Pecsi Tudomanyegyetem University of PECS (UP); The Research Institute of the Mc Gill University Health Centre (RI MUHC); Legal Pathways BV (Legal Pathways); Islensk Erfdagreining EHF (DECODE); Terveyden Ja Hyvinvoinnin Laitos (THL); International Prevention ResearchInstitut IPRI Management (IPRI); Latvijas Biomedicinas Petijumu un Studiju Centrs (LBMC); Sveuciliste U Splitu University of SPLIT (CCGH); Wroclawskie Centrum Badan EIT + Sp. z o.o. (EIT+); Klinikum Rechts der Isar der Technischen Universitat Munchen (TUM-MED); Institut national de la Sante et de lat Recherche Medicale (INSERM); MedLawconsult (Medlaw); Universiteit Maastricht (MU); Nasjonalt Folkehelseinstitutt (NIPH); Statens Serum Institut (SSI), University of Bristol (UBRIS), BBMRI-ERIC, Universita Degli Stufi di Milano Bicocca (UNIMIB)


This website was co-funded within ADOPT BBMRI-ERIC, a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 676550.
We use cookies to analyse the traffic on our websites. All personal data is anonymized and not shared with third parties! Click here for more information.